GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mydecine Innovations Group Inc (OTCPK:MYCOF) » Definitions » Shiller PE Ratio

Mydecine Innovations Group (Mydecine Innovations Group) Shiller PE Ratio : (As of Apr. 29, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Mydecine Innovations Group Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Mydecine Innovations Group Shiller PE Ratio Historical Data

The historical data trend for Mydecine Innovations Group's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mydecine Innovations Group Shiller PE Ratio Chart

Mydecine Innovations Group Annual Data
Trend Dec13 Aug14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mydecine Innovations Group Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mydecine Innovations Group's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Mydecine Innovations Group's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mydecine Innovations Group's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mydecine Innovations Group's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Mydecine Innovations Group's Shiller PE Ratio falls into.



Mydecine Innovations Group Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Mydecine Innovations Group's E10 for the quarter that ended in Sep. 2023 is calculated as:

For example, Mydecine Innovations Group's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-1.16/125.2304*125.2304
=-1.160

Current CPI (Sep. 2023) = 125.2304.

Mydecine Innovations Group Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201311 0.000 97.182 0.000
201402 0.000 98.051 0.000
201405 -10,326,877.180 99.394 -13,011,198.429
201408 0.000 99.315 0.000
201412 -19.511 98.367 -24.839
201503 -35.664 99.789 -44.756
201506 -72.787 100.500 -90.698
201509 -7.754 100.421 -9.670
201512 -32.816 99.947 -41.117
201603 -5.104 101.054 -6.325
201606 -17.450 102.002 -21.424
201609 -10.299 101.765 -12.674
201612 -151.812 101.449 -187.400
201703 -50.423 102.634 -61.525
201706 -50.771 103.029 -61.712
201709 -5.003 103.345 -6.063
201712 -140.721 103.345 -170.522
201803 -35.147 105.004 -41.917
201806 -85.800 105.557 -101.791
201809 -9.367 105.636 -11.104
201812 -88.940 105.399 -105.675
201903 -7.853 106.979 -9.193
201906 -1.881 107.690 -2.187
201909 -1.510 107.611 -1.757
201912 -21.206 107.769 -24.642
202003 -0.358 107.927 -0.415
202006 -1.845 108.401 -2.131
202009 -3.023 108.164 -3.500
202012 -3.162 108.559 -3.648
202103 -1.026 110.298 -1.165
202106 -1.432 111.720 -1.605
202109 -0.742 112.905 -0.823
202112 -1.742 113.774 -1.917
202203 -0.948 117.646 -1.009
202206 -0.273 120.806 -0.283
202209 -0.030 120.648 -0.031
202212 0.022 120.964 0.023
202303 -0.300 122.702 -0.306
202306 -0.098 124.203 -0.099
202309 -1.160 125.230 -1.160

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Mydecine Innovations Group  (OTCPK:MYCOF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Mydecine Innovations Group Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Mydecine Innovations Group's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Mydecine Innovations Group (Mydecine Innovations Group) Business Description

Traded in Other Exchanges
Address
789 West Pender Street, Suite 810, Vancouver, BC, CAN, V6C 1H2
Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.